Evgeny Degtyarev

1.1k total citations
16 papers, 236 citations indexed

About

Evgeny Degtyarev is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Evgeny Degtyarev has authored 16 papers receiving a total of 236 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Epidemiology and 5 papers in Neurology. Recurrent topics in Evgeny Degtyarev's work include Neuroendocrine Tumor Research Advances (6 papers), Lung Cancer Research Studies (6 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Evgeny Degtyarev is often cited by papers focused on Neuroendocrine Tumor Research Advances (6 papers), Lung Cancer Research Studies (6 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Evgeny Degtyarev collaborates with scholars based in Switzerland, United States and Italy. Evgeny Degtyarev's co-authors include Nicola Fazio, Philippe Ruszniewski, Catherine Lombard‐Bohas, Wouter W. de Herder, Juan W. Valle, Eric Van Cutsem, Ivan Borbath, Matthew H. Kulke, Maurizio Voi and Lida Bubuteishvili‐Pacaud and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Evgeny Degtyarev

16 papers receiving 234 citations

Peers

Countries citing papers authored by Evgeny Degtyarev

Since Specialization

Citations

This map shows the geographic impact of Evgeny Degtyarev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evgeny Degtyarev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evgeny Degtyarev more than expected).

Fields of papers citing papers by Evgeny Degtyarev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evgeny Degtyarev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evgeny Degtyarev. The network helps show where Evgeny Degtyarev may publish in the future.

Co-authorship network of co-authors of Evgeny Degtyarev

This figure shows the co-authorship network connecting the top 25 collaborators of Evgeny Degtyarev. A scholar is included among the top collaborators of Evgeny Degtyarev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evgeny Degtyarev. Evgeny Degtyarev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue? 2024 ·Future Oncology ·Evgeny Degtyarev, (unknown), Joshua Brody, Aby Buchbinder, (unknown), (unknown), Susan Halabi, Robert Hemmings, Aisha Masood, Simon Newsome, (unknown), (unknown), (unknown), Emmanuel Zuber	1
2	Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework 2024 ·Therapeutic Innovation & Regulatory Science ·Rima Izem, Emmanuel Zuber, Nadia Daizadeh, Frank Bretz, Oleksandr Sverdlov, Pascal Edrich, Janice Branson, Evgeny Degtyarev, Nikolaos Sfikas, Robert Hemmings	7
3	Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma 2023 ·Journal of Comparative Effectiveness Research ·Yanni Hao, Wei‐Chun Hsu, Craig S. Parzynski, Evgeny Degtyarev, Lisa V. Hampson, Aisha Masood, (unknown)	3
4	Combining the Target Trial and Estimand Frameworks to Define the Causal Estimand: An Application Using Real-World Data to Contextualize a Single-Arm Trial 2023 ·Statistics in Biopharmaceutical Research ·Lisa V. Hampson, Jufen Chu, Aiesha Zia, (unknown), Wei‐Chun Hsu, Craig S. Parzynski, Yanni Hao, Evgeny Degtyarev	5
5	Comparison of Clinical Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel in the Elara Trial Versus a Real-World External Control Arm of Patients Treated with Standard of Care 2021 ·Blood ·Yanni Hao, Wei‐Chun Hsu, Craig S. Parzynski, Chiara Lobetti Bodoni, Evgeny Degtyarev, Lisa V. Hampson, Aisha Masood, (unknown)	2
6	Estimands for overall survival in clinical trials with treatment switching in oncology 2021 ·Pharmaceutical Statistics ·Juliane Manitz, (unknown), Hannes Buchner, (unknown), Evgeny Degtyarev, Jyotirmoy Dey, Vincent Haddad, (unknown), Emily J. Martin, (unknown), Kaspar Rufibach, Yue Shentu, Viktoriya Stalbovskaya, Rui Tang, (unknown), (unknown)	16
7	Comment on “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment” 2021 ·Statistics in Biopharmaceutical Research ·Lisa V. Hampson, Evgeny Degtyarev, Rui Tang, Jianchang Lin, Kaspar Rufibach, Cheng Zheng	3
8	Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials—Application of the Estimand Framework 2020 ·Statistics in Biopharmaceutical Research ·Evgeny Degtyarev, Kaspar Rufibach, Yue Shentu, (unknown), Michelle Casey, Stefan Englert, Feng Liu, (unknown), (unknown), Jonathan Siegel, Steven Sun, Rui Tang, (unknown), (unknown)	18
9	Estimand framework: Are we asking the right questions? A case study in the solid tumor setting 2020 ·Pharmaceutical Statistics ·Michelle Casey, Evgeny Degtyarev, María José Lechuga, Paola Aimone, Alain Ravaud, Robert J. Motzer, Feng Liu, Viktoriya Stalbovskaya, Rui Tang, (unknown), (unknown), Susan Halabi, Daniel J. George	11
10	Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials 2019 ·JCO Precision Oncology ·Evgeny Degtyarev, Yiyun Zhang, (unknown), David Lebwohl, Mouna Akacha, Lisa V. Hampson, (unknown), (unknown), Frank Bretz, Emmanuel Zuber	14
11	Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) 2018 ·Annals of Oncology ·James C. Yao, Jonathan Strosberg, Nicola Fazio, Marianne Pavel, Philippe Ruszniewski, Emily K. Bergsland, (unknown), Salvatore Tafuto, Nitya Raj, Davide Campana, Susumu Hijioka, Markus Raderer, Rosine Guimbaud, Pablo Gajate, Sara Pusceddu, Albert Reising, Evgeny Degtyarev, Bijoyesh Mookerjee, Paola Aimone, Simron Singh	55
12	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial 2017 ·Annals of Oncology ·Matthew H. Kulke, Philippe Ruszniewski, Eric Van Cutsem, Catherine Lombard‐Bohas, Juan W. Valle, Wouter W. de Herder, Marianne Pavel, Evgeny Degtyarev, Jan C. Brase, Lida Bubuteishvili‐Pacaud, Maurizio Voi, Ramón Salazar, Ivan Borbath, Nicola Fazio, Denis Smith, Jaume Capdevila, Rachel P. Riechelmann, Jin‐Guang Yao	82
13	Health-related quality of life (HRQoL) in patients with advanced neuroendocrine tumors (NET) of gastrointestinal origin in the phase 3 RADIANT-4 trial. 2017 ·Journal of Clinical Oncology ·Simron Singh, Jonathan Strosberg, Lida Bubuteishvili‐Pacaud, Evgeny Degtyarev, Maureen P. Neary, Matthias Hünger, Jennifer Eriksson, (unknown), Nicola Fazio, Matthew H. Kulke, Marianne Pavel, James C. Yao	1
14	Association of disease progression, health-related quality of life (HRQoL), and utility in patients (pts) with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trial. 2016 ·Journal of Clinical Oncology ·Simron Singh, Marianne E. Pavel, Jonathan Strosberg, Lida Bubuteishvili‐Pacaud, Evgeny Degtyarev, Maureen P. Neary, Matthias Hünger, Jennifer Eriksson, Nicola Fazio, Matthew H. Kulke, James C. Yao	2
15	Health-related quality of life (HRQoL) in patients with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trial. 2016 ·Journal of Clinical Oncology ·Marianne Pavel, Jonathan Strosberg, Lida Bubuteishvili‐Pacaud, Evgeny Degtyarev, Maureen P. Neary, Matthias Hünger, Jennifer Eriksson, Nicola Fazio, Matthew H. Kulke, Simron Singh, James C. Yao	3
16	A randomized open-label phase II study of Everolimus alone or in combination with Pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors (pNET): COOPERATE-2 trial 2015 ·(unknown), P. Ruszniewski, Eric Van Cutsem, Juan W. Valle, Wouter W. de Herder, Anne Couvelard, Evgeny Degtyarev, (unknown), Renato Salazar, Ivan Borbath, Nicola Fazio, Catherine Lombard‐Bohas, James C. Yao	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact